Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Clinical trial NCT01763164 · COMPLETED
Trial details
- NCT number
- NCT01763164
- Sponsor
- Pfizer
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-07-12
- Primary completion
- 2015-12-01
- Enrollment
- 402
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.